Unity Biotechnology EBIT

The latest EBIT for UBX is $-38M as of March 2025. That compares with $-42M in the prior-year period — up 11.6% year over year. That is below the Healthcare sector average of $99B. Investors often review this figure alongside Unity Biotechnology's historical trend and sector peers before judging valuation or financial health.

Over the past year, UBX's EBIT moved from $-42M to $-38M — a 11.6% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Unity Biotechnology's operating scale or balance-sheet position.

Against Healthcare companies, UBX currently prints $-38M for EBIT, while the sector average sits near $99B. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Unity Biotechnology's growth, margins, and balance sheet.

A EBIT figure of $-38M for UBX is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $99B. Explore the charts below for those layers of context.

After noting UBX's EBIT ($-38M), review year-over-year change from $-42M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.